ISIS-Sanofi(Kynamro) - European due anytime this week ! Another Prostate Cance Phase-III results due before 2012 end.
Isis Pharmaceuticals, Inc.
( NASDAQ: ISIS ) ( CBOE: ISIS )
Isis Pharmaceuticals, Inc. Home
Partner : OncoGenex and Teva
Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer
Second Phase 3 Trial Evaluating Survival Benefit of Custirsen Planned to Initiate in 2012